Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From Product Launches To Toll Manufacturing, Japanese Giant Takeda Unveils Plans For India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Almost a year after naming former Roche executive Shankar Suryanarayanan as head of its Indian operations, Japan's largest drug maker Takeda has unveiled "medium- to long-term strategies" for its business expansion - one of which is to launch its products in the burgeoning Indian market

You may also be interested in...



Are Stars Finally Aligning For Takeda In India?

For the past four years, Takeda’s plans for a full-scale entry into India have remained just that – plans on paper. But will it be a laggard for much longer in this fast-changing key emerging market? There are signs that the time may now be ripe for Japan’s top pharma firm to take a more decisive plunge.

Takeda Takes First Steps In India, But How Far Will It Go?

Takeda’s plans for India are slowly taking shape, but whether it will gain speed via buyouts or go the brick- and-mortar route is the big question.

To Boost Productivity, India’s Advinus, Takeda Team Up For R&D Across Therapies

Takeda looks to ride on Advinus’ broad early-stage pipeline while also generating new INDs.

Related Content

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel